» Articles » PMID: 14592604

The Possibility of Eliminating Blinding Trachoma

Overview
Date 2003 Nov 1
PMID 14592604
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Global elimination of blinding trachoma, the world's leading preventable cause of blindness, now seems possible. The disease, which persists most severely in the poorest parts of Africa and Asia, is already eliminated in North America and Europe. On a scientific basis, the case for elimination was outlined at a WHO global scientific meeting in 1996. To facilitate action, WHO founded the Alliance for Global Elimination of Trachoma by 2020 (GET 2020) in 1997. In 1998 a World Health Assembly resolution called for member states to take steps to eliminate blinding trachoma by 2020 using the WHO recommended SAFE strategy (surgery of late stage disease, antibiotics for acute infection, and improved facial hygiene and environmental change-ie, improved access to water and sanitation). These developments contributed to the decision by Pfizer Inc to donate azithromycin in support of national programmes implementing SAFE and, with the Edna McConnell Clark Foundation, to found the International Trachoma Initiative as a charity dedicated to the elimination of blinding trachoma by 2020. Reports of the early programme scope and impact are encouraging. In ten national programmes currently underway (constituting about 50% of the global burden) more than 55,000 lid surgeries have halted further corneal damage and prevented blindness, and more than 6 million treatments with azithromycin have been given with reductions in acute infections of around 50% in children. Morocco, one of the first countries to implement SAFE with azithromycin, has achieved remarkable results and expects to eliminate blinding trachoma by 2005. If political will and public-health support can be mobilised, the goal of eliminating this cause of blindness can become a reality by 2020.

Citing Articles

The elimination of trachoma as a public health problem in Togo: Successes and challenges.

Bakoubayi A, Gadah D, Gnossike P, Zida-Compaore W, Bando P, Alaglo K PLoS Negl Trop Dis. 2023; 17(7):e0011444.

PMID: 37463175 PMC: 10353810. DOI: 10.1371/journal.pntd.0011444.


The Weight of Evidence From Electrophysiology, Observational, and Cardiovascular End Point Studies Demonstrates the Safety of Azithromycin.

Cook J, Pressler M, Damle B, Alemayehu D, Knirsch C Clin Transl Sci. 2020; 14(1):106-112.

PMID: 32956575 PMC: 7537091. DOI: 10.1111/cts.12867.


Viability PCR shows that non-ocular surfaces could contribute to transmission of Chlamydia trachomatis infection in trachoma.

Versteeg B, Vasileva H, Houghton J, Last A, Shafi Abdurahman O, Sarah V PLoS Negl Trop Dis. 2020; 14(7):e0008449.

PMID: 32667914 PMC: 7384675. DOI: 10.1371/journal.pntd.0008449.


Detecting extra-ocular Chlamydia trachomatis in a trachoma-endemic community in Ethiopia: Identifying potential routes of transmission.

Last A, Versteeg B, Shafi Abdurahman O, Robinson A, Dumessa G, Abraham Aga M PLoS Negl Trop Dis. 2020; 14(3):e0008120.

PMID: 32130213 PMC: 7075638. DOI: 10.1371/journal.pntd.0008120.


Elimination of trachoma as a public health problem in Ghana: Providing evidence through a pre-validation survey.

Debrah O, Mensah E, Senyonjo L, de Souza D, Hervie T, Agyemang D PLoS Negl Trop Dis. 2017; 11(12):e0006099.

PMID: 29232708 PMC: 5746280. DOI: 10.1371/journal.pntd.0006099.